@prefix this: <http://purl.org/np/RAmBxV9NwPCJF00tOcDOvIaWVPltHn-LOIupuYkqY93fI> .
@prefix sub: <http://purl.org/np/RAmBxV9NwPCJF00tOcDOvIaWVPltHn-LOIupuYkqY93fI#> .
@prefix drugbank: <http://identifiers.org/drugbank/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix mondo: <http://purl.obolibrary.org/obo/MONDO_> .
@prefix pav: <http://purl.org/pav/> .
@prefix infores: <https://w3id.org/biolink/infores/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix ntemplate: <https://w3id.org/np/o/ntemplate/> .
@prefix orcid: <https://orcid.org/> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix pmid: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix ncit: <http://purl.obolibrary.org/obo/NCIT_> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo;
    a np:Nanopublication .
}

sub:assertion {
  drugbank:DB01267 a biolink:Drug;
    rdfs:label "Paliperidone";
    biolink:category biolink:Drug .
  
  mondo:0005090 a biolink:Disease;
    rdfs:label "Manic bipolar affective disorder";
    biolink:category biolink:Disease .
  
  sub:association rdf:object mondo:0005090;
    rdf:predicate biolink:treats;
    rdf:subject drugbank:DB01267;
    a biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    rdfs:label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)";
    biolink:aggregator_knowledge_source infores:knowledge-collaboratory;
    biolink:category biolink:ChemicalToDiseaseOrPhenotypicFeatureAssociation;
    biolink:has_population_context sub:context;
    biolink:publications pmid:31096228;
    biolink:relation ncit:C94303 .
  
  sub:context a biolink:Cohort;
    rdfs:label "Children and adolescents (6-17 years)";
    biolink:category biolink:Cohort .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-7641-6446 .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB";
    npx:hasSignature "MvwpmExq3ICFcY5B+BxMqvEkyn/L4WcUEGBvg9Ii25zQa3w/jFNhelcF/DdrqKosngpIawhpYivo17fgcaqod1wGoOgHleTBJ4T/LQeTcm6ctNvQDNGFmiht0AaftchduTGtIvRilMbSTy7pSCCxwMzXhtxU1YHX/12CM/5aQJ4=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2022-09-16T11:50:40.267580"^^xsd:dateTime;
    prov:wasAttributedTo orcid:0000-0002-1501-1082;
    ntemplate:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
  
  biolink: pav:version "2.3.0" .
}